Changmao Biochemical Engineering Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Changmao Biochemical Engineering hat ein Gesamteigenkapital von CN¥651.6M und eine Gesamtverschuldung von CN¥492.6M, wodurch sich der Verschuldungsgrad auf 75.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥1.2B bzw. CN¥590.9M. Changmao Biochemical Engineering Das EBIT des Unternehmens beträgt CN¥21.6M, so dass der Zinsdeckungsgrad 3.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥96.6M.

Wichtige Informationen

75.6%

Verhältnis von Schulden zu Eigenkapital

CN¥492.61m

Verschuldung

Zinsdeckungsgrad	3.3x
Bargeld	CN¥96.56m
Eigenkapital	CN¥651.59m
Gesamtverbindlichkeiten	CN¥590.91m
Gesamtvermögen	CN¥1.24b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Aug 02

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Nov 18

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Apr 28

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Aug 03

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

May 04

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Feb 23

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

Jan 26

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

Dec 02

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 954Die kurzfristigen Aktiva des Unternehmens (CN¥338.3M) übersteigen seine kurzfristigen Passiva (CN¥325.2M).

Langfristige Verbindlichkeiten: 954Die kurzfristigen Vermögenswerte des Unternehmens (CN¥338.3M) übersteigen seine langfristigen Verbindlichkeiten (CN¥265.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 954Die Nettoverschuldung im Verhältnis zum Eigenkapital (60.8%) wird als hoch angesehen.

Schulden abbauen: 954Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 6.2% auf 75.6% gestiegen.

Schuldendeckung: 954Der operative Cashflow des Unternehmens ist negativ, so dass die Schulden nicht ausreichend gedeckt sind.

Zinsdeckung: Die Zinszahlungen für die Schulden von 954 sind durch das EBIT gut gedeckt (3.3x coverage).

Changmao Biochemical Engineering Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

Chairman & Compliance Officer recently bought HK$132k worth of stock

Chairman & Compliance Officer recently bought HK$836k worth of stock

Chairman & Compliance Officer recently bought HK$164k worth of stock

Changmao Biochemical Engineering Company Limited, Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CN¥0.16 loss per share (vs CN¥0.15 profit in FY 2022)

New minor risk - Financial data availability

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Chairman & Compliance Officer recently bought HK$59k worth of stock

Chairman & Compliance Officer recently bought HK$231k worth of stock

Chairman & Compliance Officer recently bought HK$54k worth of stock

Chairman & Compliance Officer recently bought HK$327k worth of stock

Chairman & Compliance Officer recently bought HK$277k worth of stock

New major risk - Financial position

First half 2023 earnings released: EPS: CN¥0.008 (vs CN¥0.077 in 1H 2022)

Changmao Biochemical Engineering Company Limited to Report First Half, 2023 Results on Aug 18, 2023

Investors Will Want Changmao Biochemical Engineering's (HKG:954) Growth In ROCE To Persist

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Changmao Biochemical Engineering Company Limited approves Final Dividend for the Year Ended 31 December 2022, Payable on 18 July 2023

Upcoming dividend of CN¥0.077 per share at 8.4% yield

Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in FY 2021)

Returns On Capital At Changmao Biochemical Engineering (HKG:954) Have Stalled

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.077 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited Announces Appointment of Ms. Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee, and Member of Remuneration Committee and Nomination Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0 in 1H 2021)

Changmao Biochemical Engineering Company Limited to Report First Half, 2022 Results on Aug 18, 2022

Changmao Biochemical Engineering Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Changmao Biochemical Engineering Company Limited Appoints Cheng Mun Wah as Independent Non-Executive Director and Chairman of Audit Committee and Member of Remuneration Committee and Nomination Committee

Changmao Biochemical Engineering Company Limited Approves Board Resignations, Effective 18 June 2022

We Believe Changmao Biochemical Engineering's (HKG:954) Earnings Are A Poor Guide For Its Profitability

Less than half of directors are independent

Changmao Biochemical Engineering Company Limited Omits Final Dividend for the Year Ended 31 December 2021

Full year 2021 earnings released

Changmao Biochemical Engineering (HKG:954) Will Be Looking To Turn Around Its Returns

Upcoming dividend of CN¥0.02 per share

Changmao Biochemical Engineering (HKG:954) May Have Issues Allocating Its Capital

Full year 2020 earnings released: EPS CN¥0.032 (vs CN¥0.11 in FY 2019)

Full year 2020 earnings released

Changmao Biochemical Engineering Company Limited Provides Earnings Guidance for the Year Ended 31 December 2020

Changmao Biochemical Engineering Company Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Tread With Caution Around Changmao Biochemical Engineering Company Limited's (HKG:954) 8.8% Dividend Yield

Will Changmao Biochemical Engineering (HKG:954) Multiply In Value Going Forward?

New 90-day high: HK$0.65

A Quick Analysis On Changmao Biochemical Engineering's (HKG:954) CEO Salary

New 90-day low: HK$0.56

First half earnings released

New 90-day low - HK$0.59

First half earnings released

Changmao Biochemical Engineering Company Limited to Report First Half, 2020 Results on Aug 28, 2020

New 90-day low - HK$0.60

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen